Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Find therapies in clinical trials near you – page 126

recruiting
3 987
countries
28
conditions
2 109

1 824 trials match your criteria

Mantle cell lymphoma

Not recruiting

Study of Zanubrutinib and Rituximab Compared to Bendamustine and Rituximab for Patients with Untreated Mantle Cell Lymphoma Ineligible for Stem Cell Transplant

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Rituximab

Asthma

Not recruiting

Study on the Effects of Povorcitinib for Adults with Moderate to Severe Asthma Not Well Controlled

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib

Glycogen storage disease type I

Not recruiting

Study on the Safety and Effects of mRNA-3745 for Patients with Glycogen Storage Disease Type 1a (GSD1a)

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years
  • Substances:Codeine Phosphate

Fatty acid oxidation disorder

Not recruiting

Study on the Effects of Triheptanoin and Medium-chain Triglycerides in Children with Long-chain Fatty Acid Oxidation Disorders

Registered drugNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Doconexent

Chronic lymphocytic leukaemia

Not recruiting

Study Comparing Pirtobrutinib to Bendamustine and Rituximab for Untreated Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Pirtobrutinib

B-cell lymphoma+5

Not recruiting

Study on the Effects and Safety of Odronextamab for Adults with Previously Treated B-cell Non-Hodgkin Lymphoma

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Odronextamab

Adenocarcinoma gastric+1

Not recruiting

Study of MK-2870 for Patients with Advanced or Metastatic Stomach Cancer, Comparing Its Effects to a Drug Combination

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Codeine Phosphate

Dermatitis atopic

Not recruiting

Study on Amlitelimab for Patients Aged 12 and Older with Moderate to Severe Atopic Dermatitis Using Topical Corticosteroids and Inadequate Response to Previous Treatments

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Amlitelimab

Gastrointestinal melanoma+7

Not recruiting

Study of Encorafenib, Binimetinib, and Pembrolizumab for Patients with Advanced Melanoma with BRAF V600E/K Mutation

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Binimetinib

Heart failure with preserved ejection fraction

Not recruiting

Study on the Safety and Effectiveness of Tovinontrine for Adults with Chronic Heart Failure with Preserved Ejection Fraction

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tovinontrine

Bladder transitional cell carcinoma

Not recruiting

Study of RO7247669, Tiragolumab, and Atezolizumab for Patients with Untreated Advanced Urothelial Cancer Ineligible for Platinum Chemotherapy

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab

Chronic cutaneous lupus erythematosus

Not recruiting

Study of daxdilimab injection for adults with moderate to severe discoid lupus erythematosus

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Daxdilimab

Explore other searches

Helpful resources

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.